Q2 EPS Forecast for Eton Pharmaceuticals Boosted by Analyst

Eton Pharmaceuticals, Inc. (NASDAQ:ETONFree Report) – Investment analysts at HC Wainwright raised their Q2 2025 earnings per share estimates for Eton Pharmaceuticals in a report released on Thursday, January 23rd. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.17 per share for the quarter, up from their previous forecast of $0.08. HC Wainwright has a “Buy” rating and a $33.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q3 2025 earnings at $0.26 EPS, Q4 2025 earnings at $0.34 EPS, FY2025 earnings at $0.81 EPS, FY2026 earnings at $2.01 EPS, FY2027 earnings at $2.63 EPS, FY2028 earnings at $3.82 EPS and FY2029 earnings at $4.89 EPS.

Several other equities analysts have also recently issued reports on the stock. B. Riley began coverage on shares of Eton Pharmaceuticals in a research note on Friday, January 10th. They issued a “buy” rating and a $21.00 price objective on the stock. Craig Hallum increased their price objective on Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th.

View Our Latest Stock Analysis on ETON

Eton Pharmaceuticals Stock Down 1.3 %

Shares of ETON stock opened at $16.46 on Monday. The stock has a 50-day simple moving average of $12.97 and a 200 day simple moving average of $8.37. The stock has a market capitalization of $428.78 million, a P/E ratio of -74.82 and a beta of 1.38. Eton Pharmaceuticals has a fifty-two week low of $3.03 and a fifty-two week high of $17.35.

Hedge Funds Weigh In On Eton Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC acquired a new position in Eton Pharmaceuticals during the second quarter valued at $3,095,000. Wasatch Advisors LP purchased a new position in Eton Pharmaceuticals during the third quarter valued at approximately $1,431,000. Aristides Capital LLC acquired a new position in Eton Pharmaceuticals in the 2nd quarter valued at approximately $658,000. Stonepine Capital Management LLC acquired a new stake in shares of Eton Pharmaceuticals during the 2nd quarter valued at $362,000. Finally, Renaissance Technologies LLC grew its holdings in shares of Eton Pharmaceuticals by 63.8% during the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after acquiring an additional 41,469 shares in the last quarter. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

About Eton Pharmaceuticals

(Get Free Report)

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.

Further Reading

Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.